Currently Viewing:
The International Society for Pharmacoeconomics and Outcomes Research
Value Assessment Frameworks Should Represent a Spectrum of Patient Preferences
September 08, 2017
Dr Patricia Danzon: Learning From European Health Systems
August 30, 2017
Dr Ilene Hollin: One-Size-Fits-All to Value Doesn't Work
August 23, 2017
Dr Patricia Danzon Highlights European Examples of Restraining Drug Prices
August 16, 2017
Dr Ilene Hollin Outlines Differing Definitions of Value
August 09, 2017
Dr Patricia Danzon: Cost Effective Doesn't Mean Affordable
August 03, 2017
Dr Michael Sherman on Performance-Based Risk-Sharing Agreements
July 28, 2017
Dr David Cutler Assesses the Political Odds of Drug Pricing Reform
July 25, 2017
Dr Steve Pearson on Using Health Technology Assessment to Guide Decision Making
July 23, 2017
Dr Gail Wilensky: Increased Competition a Better Drug Pricing Solution Than Cost Controls
July 16, 2017
Dr Steve Pearson on Data Needed to Evaluate Clinical and Economic Effects of New Therapies
July 14, 2017
Dr David Cutler: Trump Administration's Attention Not on Value-Based Purchasing
July 09, 2017
Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations
July 06, 2017
Currently Reading
Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development
July 04, 2017
Dr Gail Wilensky Raises Questions About Medicaid's Matching Grant Structure
June 25, 2017
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
June 22, 2017
Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform
June 20, 2017
Dr Scott Ramsey on Challenges of Determining Cost Effectiveness of Novel Cancer Treatments
June 19, 2017
Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework
June 18, 2017

Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development

According to Steve Pearson, MD, MSc, president of the Institute for Clinical and Economic Review (ICER), patient perspectives are critical for determining meaningful outcomes and helping to guide the cost-effectiveness review process.


According to Steve Pearson, MD, MSc, president of the Institute for Clinical and Economic Review (ICER), patient perspectives are critical for determining meaningful outcomes and helping to guide the cost-effectiveness review process.

Transcript (slightly modified)

How does ICER work to incorporate patient perspectives into its value frameworks?

Patient perspectives, in a sense, guide almost every step we take in our report process. At the very beginning, when we’re just thinking of which topics to do, we reach out to patient groups to make sure, as part of what we call our scoping phase, that we really understand what living with the condition is like from their perspective. We know that they have heard policy makers sometimes, if it’s an organized patient group, they’ve heard policy makers, they’ve heard clinicians sometimes get it wrong, where they don’t understand the full spectrum. They don’t understand what really matters most to patients.

Now, we always have questions of our own. We want to know, for instance, specifically, are there clinical outcome measures that are in the clinical trials that they think are more important to the patients than others, so that they can help us prioritize those. Again, that’s a really critical part because that feeds into every step of our process from the review of clinical excellence through to the cost-effectiveness model.

We establish those relationships, we try to make sure we get a diverse set of patients and patient groups by reaching out to as many as we can find, and then again at that scoping phase, it’s critical. We also feed back to them our early results and make sure that they get a chance to have input. We often have, in a sense, a patient expert be one of the official reviewers of our draft report before it goes out for more full public comment.

That all happens before we even have our public meeting, which is the other place where we bring all stakeholders together, but patients and the clinical experts have a very important role right at the beginning of the day, where they often are involved as the summary of the evidence is being presented, and they’re given the opportunity to lend nuance to that, to give a broader perspective, if you will.

Then, they sit at the table as our independent counsels discuss the evidence and start to get ready to vote, so that if questions come up, they’re right there in the midst of the conversation to be able to help lend that broader perspective, and sometimes answer very specific questions about key issues of evidence and value from the patient’s perspective.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!